LNA043 + Placebo
Phase 1CompletedDevelopment Stage
Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
Nov 16, 2015 → Mar 6, 2018
About LNA043 + Placebo
LNA043 + Placebo is a phase 1 stage product being developed by Novartis for Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT02491281. Target conditions include Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery.
What happened to similar drugs?
20 of 20 similar drugs in Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery were approved
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04564053 | Phase 1 | Completed |
| NCT02491281 | Phase 1 | Completed |
Competing Products
20 competing products in Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery